InterMune Inc. announced that the on-going Phase 2b study conducted by Hoffmann-LaRoche Inc. and F.Hoffmann-La Roche Ltd., or Roche, of ITMN-191 combined with standard of care, or SOC, PEGASYS � (peginterferon alfa-2a) and COPEGUS � (ribavirin) in chronic hepatitis C virus (HCV) treatment-na�ve patients has been modified. The Phase 2b study has four dosage cohorts, SOC, 300mg every 8 hours plus SOC, 600mg every 12 hours plus SOC and 900mg every 12 hours plus SOC. To date, approximately 175 patients have been enrolled in the study. Three patients in the 900 mg every 12 hours dosage cohort experienced a Grade 4 elevation in ALT levels, one of whom experienced an elevation of total bilirubin while also receiving concomitant allopurinol. After their review of the un-blinded data from all cohorts, the study's independent Data Monitoring Committee (DMC) recommended that the 900mg every 12 hours cohort be discontinued and that all other cohorts of the study continue. The companies accepted the DMC's recommendations. The on-going Phase 2b study is blinded and, consequently, additional information will not be provided. The company expects to announce the results of blinded rapid virological response (RVR) data from the 12-week treatment duration cohorts of the Phase2b study in the first quarter of 2010 as previously disclosed. The company also reported that the on-going ritonavir boosting study of low-dose ITMN-191 continues to enroll patients and that guidance provided by the company on November 3, 2009 for INFORM-2 and a longer duration Phase 2 study of the combination of direct acting antivirals to evaluate sustained virologic response (SVR) is not expected to change at this time.

InterMune Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. The company reported net loss of $8.8 million or $0.19 per share compared with a net loss of $14.0 million or $0.36 per share in the third quarter of 2008. InterMune reported total revenue in the third quarter of 2009 of $27.3 million compared with total revenue of $23.3 million in the third quarter of 2008. Total revenue in the third quarter of 2009 primarily consisted of revenue from the collaboration with Roche for the development of protease inhibitors, including ITMN-191, which totaled $20.8 million in the third quarter of 2009, compared with $15.8 million in the third quarter of 2008. Loss from operations was $6.0 million against $11.9 million last year. Loss from continuing operations was $8.7 million or $0.19 per basic and diluted share against $13.9 million or $0.36 per basic and diluted share last year. For the nine months, net loss was $87.4 million or $2.00 per share compared with a net loss of $72.7 million or $1.87 per share in the first nine months of 2008. Total revenue in the first nine months of 2009 was $42.1 million, compared with total revenue of $40.8 million in the same period of 2008, an increase of 3%. Loss from operations was $74.5 million against $67.2 million last year. Loss from continuing operations was $87.4 million or $2.00 per basic and diluted share against $72.7 million or $1.87 per basic and diluted share last year. The company updated its 2009 financial guidance for revenue and operating expenses from the guidance initially provided on February 26, 2009. 2009 revenue, including Actimmune� and milestone payments from Roche, is expected to be in a range of approximately $45 to $50 million. Actimmune revenue represents approximately 50% of this revenue range.

InterMune Inc. announced additions to its senior leadership team to prepare for the potential commercialization of pirfenidone in the United States and Europe. The company appointed Ms. Terri Shoemaker as Vice President of Sales. Ms. Shoemaker has held senior commercial leadership positions at Du Pont Pharmaceuticals, Bristol-Myers Squibb, Pharmion and Celgene. Most recently at Pharmion (acquired by Celgene), Ms. Shoemaker was responsible for creating the commercial organization and the successful launch of Vidaza�. The company also appointed Mr. Erik Harris as Vice President of Marketing. Mr. Erik Harris has held senior positions in marketing and sales management at Bristol-Myers Squibb, Genentech and Elan. At Genentech, he held sales and marketing management positions, notably as Group Brand Manager for Rituxan� and Tarceva�. Most recently at Elan, he was a Senior Director of Marketing and Sales in Gastroenterology prior to becoming Senior Director of Strategic Brand Management for Gastroenterology and Neurology. Mr. Harris will assume his responsibilities with InterMune on November 16, 2009. The company also appointed Mr. Darren Cline as Vice President of Managed Care and Access. Mr. Darren Cline has held senior sales, marketing and managed care roles at Schering-Plough, Amgen, InterMune and most recently, Alexion. At Alexion, he served as Executive Director of Sales and played an integral role in the successful launch of Soliris�. These three executives will report to Barrett McGrath, who was announced as InterMune's Vice President of Sales and Marketing on August 6, 2009. The company also announced that Mr. Giacomo di Nepi has been appointed to the newly created position of Senior Vice President and General Manager, Europe. Mr. di Nepi held senior roles at the global and country management levels with Novartis. After Novartis, Mr. di Nepi was the EU General Manager for Takeda where he led EU operations and geographic expansion. Prior to Takeda and Novartis, he was a partner at McKinsey & Co., specializing in healthcare. Mr. di Nepi will report to Mr. Welch.